A randomized, controlled study of thymosin-α1 therapy in patients with anti-HBe, HBV-DNA-positive chronic hepatitis B

Digestive Diseases and Sciences

Volumn 45, Issue 4, 2000, Pages 690-696

  Zavaglia, Claudio ^a,b,c,d   Severini, Remo ^a,b,c   Tinelli, Carmine ^a,b,c   Franzone, Josè S ^a,b,c   Airoldi, Aldo ^a,b,c   Tempini, Silvana ^a,b,c   Bettale, Giuseppina ^a,b,c   Ideo, Gaetano ^a,b,c  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b Direzione Medica   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

Chronic hepatitis B; Therapy; Thymosin 1

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; HEPATITIS B CORE ANTIBODY; HEPATITIS B(E) ANTIBODY; IMMUNOGLOBULIN M; THYMOSIN ALPHA1; VIRUS DNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HORMONAL THERAPY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; LIVER HISTOLOGY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VIRUS LOAD;

ADJUVANTS, IMMUNOLOGIC; ADULT; DNA, VIRAL; FEMALE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; THYMOSIN; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034112421     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005431323945     Document Type: Article

References (35)

1. 1. Hadziyannis SJ, Lieberman HM, Karvountzis GG, Shafritz DA: Analysis of liver disease, nuclear HBcAg, viral replication, and hepatitis B virus DNA in liver and serum of HBeAg vs. antiHBe positive carriers of hepatitis B virus. Hepatology 3:656-662, 1983
2. 2. Fattovich G, Rugge M, Brollo L, Pontisso P, Noventa F, Guido M, Alberti A, Realdi G: Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 6:167-172, 1986
3. 3. Bonino F, Rosina F, Rizzetto M, Rizzi R, Chiaberge E, Tardanico R, Callea F, Verme G: Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology 90:1268-1273, 1986
4. 4. Carman WF, Jacyna MR, Hadziyannis S, Karayiannis P, McGarvey MJ, Makris A, Thomas HC: Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet 2:588-591, 1989
5. 5. Brunetto MR, Stemler M, Schödel F, Will H, Ottobrelli A, Rizzetto M, Verme G, Bonino F: Identification of HBV variants which cannot produce precore derived HBeAg and may be responsible for severe hepatitis. Ital J Gastroenterol 21:151-154, 1989
6. 6. Mels GC, Bellati G, Leandro G, Brunetto MR, Vicari O, Borzio M, Piantino P, Fornaciari G, Scudeller G, Angeli G, Bonino F, Ideo G: Fluctuations in viremia, aminotransferases and IgM antibody to hepatitis B core antigen in chronic hepatitis B patients with disease exacerbations. Liver 14:175-181, 1994
7. 7. Brunetto MR, Oliveri F, Rocca G, Criscuolo D, Chiaberge E, Capalbo M, David E, Verme G, Bonino F: Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 10:198-202, 1989
8. 8. Hadziyannis S, Bramou T, Makris A, Moussoulis G, Zignego L, Papaioannou C: Interferon alfa-2b treatment of HBeAg-negative/serum HBV-DNA-positive chronic active hepatitis type B. J Hepatol 11:S133-S136, 1990
9. 9. Pastore G, Santantonio T, Milella M, Monno L, Mariano N, Moschetta R, Pollice L: Anti-HBe-positive chronic hepatitis B with HBV-DNA in the serum response to a 6-month course of lymphoblastoid interferon. J Hepatol 14:221-225, 1992
10. 10. Fattovich G, Farci P, Rugge M, Brollo L, Mandas A, Pontisso P, Giustina G, Lai ME, Belussi F, Busatto G, Balestrieri A, Ruol A, Alberti A: A randomized controlled trial of lymphoblastoid interferon-α in patients with chronic hepatitis B lacking HBeAg. Hepatology 15:584-589, 1992
11. 11. Sztein MB, Goldstein AL: Thymic hormones - a clinical update. Springer Semin Immunopathol 9:1-18, 1986
12. 12. Goldstein AL: Clinical applications of thymosin alpha-1. Cancer Invest 12:545-547, 1994
13. 13. Ernst E: Thymus therapy for cancer? A criteria-based, systematic review. Eur J Cancer 33:531-535, 1997
14. 14. Mutchnick MG, Appelman HD, Chung HT, Aragona E, Gupta TP, Cummings GD, Waggoner JG, Hoofnagle JH, Shafritz DA: Thymosin treatment of chronic hepatitis B: A placebo-controlled pilot trial. Hepatology 14:409-415, 1991
15. 15. Zavaglia C, Bottelli R, Smedile A, Iamoni G, Mondazzi L, Airoldi A, Lanzani F, Ideo G: A pilot study of thymosin-α1 therapy for chronic hepatitis D. J Clin Gastroenterol 23:162-163, 1996
16. 16. Andreone P, Cursaro C, Gramenzi A, Zavaglia C, Rezakovic I, Altomare E, Severini R, Franzone JS, Albano O, Ideo G, Bernardi M, Gasbarrini G: A randomized controlled trial of thymosin-α1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody-and hepatitis B virus DNA-positive chronic hepatitis B. Hepatology 24:774-777, 1996
17. 17. Chisari FV, Ferrari C: Viral Hepatitis. In Viral Pathogenesis. N Nathanson (ed) Lippincott-Raven Publishers. Philadelphia 1997. pp 745-778
18. 18. Casagrande JT, Pike MC: An improved approximate formula for calculating sample sizes for comparing two binomial distributions. Biometrics 34:483-486, 1978
19. 19. Rezakovic I, Zavaglia C, Bottelli R, Ideo G. Sustained response to thymosin alpha 1 therapy in chronic HBsAg. HBeAb, HBVDNA positive hepatitis. Ital J Gastroenterol 25(suppl. 1):150-151, 1993 (abstract)
20. 20. Kuhns MC, McNamara AL, Cabal CM, Decker RH, Thiers V, Bréchot C, Tiollais P: A new assay for the quantitative detection of hepatitis B viral DNA in human serum. In Viral Hepatitis and Liver Disease. AJ Zuckerman (ed). Alan R. Liss, New York, 1988, pp 258-262
21. 21. Scheuer PJ: Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 13:372-374, 1991
22. 22. Zavaglia C, Mondazzi L, Maggi G, Iamoni G, Gelosa F, Bellati G, Colloredo G, Bottelli R, Ideo G: Are alanine-aminotransferase, hepatitis B virus DNA or IgM antibody to hepatitis B core antigen serum levels predictors of histological grading in chronic hepatitis B? Liver 17:83-87, 1997
23. 23. Marinos G, Smith HM, Naoumov NV, Williams R: Quantitative assessment of serum IgM anti-HBc in the natural course and during interferon treatment of chronic hepatitis B virus infection. Hepatology 19:303-311, 1994
24. 24. Brunetto MR, Cerenzia MT, Oliveri F, Piantino P, Randone A, Calvo P-L, Manzini P, Rocca G, Galli C, Bonino F: Monitoring the natural course and response to therapy of chronic hepatitis B with an automated semi-quantitative assay for TgM anti-HBc. J Hepatol 19:431-436, 1993
25. 25. Matthews JNS, Altman GB, Campbell MJ, Royston P: Analysis of serial measurements in medical research. Br Med J 300:230-235, 1990
26. 26. Liaw Y-F, Tai D-I, Chu C-M, Chen T-J: The development of cirrhosis in patients with chronic type B hepatitis: A prospective study. Hepatology 8:493-496, 1988
27. 27. Fattovich G, Brollo L, Giustina G, Noventa F, Pontisso P, Alberti A, Realdi G, Ruol A: Natural history and prognostic factors for chronic hepatitis type B. Gut 32:294-298, 1991
28. 28. Lampertico P, Del Ninno E, Manzin A, Donato MF, Rumi MG, Lunghi G, Morabito A, Clementi M, Colombo M: A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 26:1621-1625, 1997
29. 29. Sherman KE, Jones CC, Goldstein AL, Naylor PH: Low thymosin alpha-1 concentrations in patients chronically infected with the hepatitis B virus. Viral Immunol 4:195-199, 1991
30. 30. Chien RN, Liaw Y-F, Chen T-C, Yeh C-T, Sheen I-S: Efficacy of thymosin-α1 in patients with chronic hepatitis B: A randomized, controlled trial. Hepatology 27:1383-1387, 1998
31. 31. Wang BE, Yu CZ, Thien GS, Tao QM, Liu DG, Min ZL, Wu SM, Yao JL, Lu WL, Peng WW, China Thymosin-α1 Study Group: Treatment of chronic hepatitis B with thymosin-α1: experiences in China. Hepatology 26:626A, 1997
32. 32. Fang BF, Sun Y, Wang H, Zhang L, Tao QM: A pilot study of thymosin-α1 for the treatment of chronic hepatitis B. Hepatology 26:504A, 1997
33. 33. Colloredo G, Bellati G, Sonzogni A, Zavaglia C, Fracassetti O, Leandro G, Ghislandi R, Minola E, Ideo G: Semiquantitative assessment of IgM antibody to hepatitis B core antigen and prediction of the severity of chronic hepatitis B. J Viral Hepatitis 6:423-434, 1999
34. 34. Moshier JA, Mutchnick MG, Dosescu J, Holtz TK, Akkary S, Mahakala K, Merline JR, Naylor PH: Thymosin-α1, but not interferon-α, specifically inhibits anchorage-independent growth of hepatitis B viral transfected HepG2 cells. J Hepatol 25:814-820, 1996
35. 35. Rasi G, Mutchnick MG, Di Virgilio D, Sinibaldi-Vallebona P, Pierimarchi P, Colella F, Favalli C, Garaci E: Combination low-dose lymphoblastoid interferon and thymosin-α1 therapy in the treatment of chronic hepatitis B. J Viral Hepatitis 3:191-196, 1996